NCT02224456 - Efficacy and Safety Study of Tenofovir Disoproxil Fumarate (TDF) in Chinese Chronic Hepatitis B (CHB) Subjects With Advanced Fibrosis & Compensated Cirrhosis | Biotech Hunter

Enrollment

197

Participants

Timeline

Start Date

March 25, 2015

Primary Completion Date

December 4, 2020

Study Completion Date

December 4, 2020

Conditions

Hepatitis B, Chronic

Interventions

DRUG

Tenofovir disoproxil fumarate

"White, almond-shaped, film-coated tablet containing 300 mg of TDF, debossed with GILEAD and 4331 on one side of the tablet."

Trial Locations (19)

100044

GSK Investigational Site, Beijing

100050

GSK Investigational Site, Beijing

100069

GSK Investigational Site, Beijing

130000

GSK Investigational Site, Changchun

200025

GSK Investigational Site, Shanghai

200040

GSK Investigational Site, Shanghai

201508

GSK Investigational Site, Shanghai

210002

GSK Investigational Site, Nanjing

210003

GSK Investigational Site, Nanjing

250021

GSK Investigational Site, Jinan

310000

GSK Investigational Site, Hangzhou

400038

GSK Investigational Site, Chongqing

430022

GSK Investigational Site, Wuhan

450000

GSK Investigational Site, Zhengzhou

510060

GSK Investigational Site, Guangzhou

610041

GSK Investigational Site, Chengdu

710038

GSK Investigational Site, Xian

710061

GSK Investigational Site, Xi'an

030001

GSK Investigational Site, Taiyuan